Yabao Pharmaceutical Group Co., Ltd (SHA: 600351), a Chinese pharmaceutical company, has announced that SY-009 capsules, a sodium-glucose linked transporter-1 (SGLT-1) inhibitor co-developed with Eli Lilly & Co., (NYSE: LLY) have received approval from the National Medical Products Administration (NMPA) to proceed to a Phase II clinical study for the treatment of functional constipation.
Yabao licensed the development and commercialization rights for an SGLT-1 inhibitor in China from Eli Lilly under a deal reported in October 2015. In July 2017, the company announced it had received clinical trial approval for SY-008, another SGLT-1 molecule with different specifications of 2mg, 10mg, and 20mg. SY-009 is also under Phase II study for type 2 diabetes, with the indication receiving trial approval in August 2018.
Functional constipation is primarily caused by weakened gastrointestinal peristalsis and uncoordinated intestinal movement. The condition is more prevalent in women than in men and its incidence increases with age. Among Chinese individuals aged 60 and above, the incidence rate is between 15% and 20%.- Flcube.com
